

# Thrombospondin 1 Monoclonal Antibody (A6.1)

## Product Details

Size	200 µL
Species Reactivity	Bovine, Dog, Horse, Human, Mouse, Sheep, Pig, Rat
Published Species	Rat, Sheep, Human, Mouse
Host/Isotype	Mouse / IgG1
Class	Monoclonal
Type	Antibody
Clone	A6.1
Conjugate	Unconjugated
Immunogen	Reduced and alkylated purified human TSP (fully denatured) from the supernatant of thrombin-activated platelets
Form	Liquid
Concentration	0.5 mg/mL
Purification	Protein G
Storage buffer	PBS, pH 7.2
Contains	0.09% sodium azide
Storage conditions	4° C
RRID	AB_10984611



Applications	Tested Dilution	Publications
Western Blot (WB)	1-2 µg/mL	52 Publications
Immunohistochemistry (IHC)	-	42 Publications
Immunohistochemistry (Paraffin) (IHC (P))	1:25-1:50	2 Publications
Immunohistochemistry (Frozen) (IHC (F))	-	1 Publication
Immunocytochemistry (ICC/IF)	1:20-1:200	6 Publications
Flow Cytometry (Flow)	Assay-dependent	-
ELISA (ELISA)	-	3 Publications
Immunoprecipitation (IP)	2 µg/mL	3 Publications
Neutralization (Neu)	-	4 Publications
Dot blot (DB)	-	2 Publications
Immunomicroscopy (IM)	Assay-dependent	-
Miscellaneous PubMed (Misc)	-	1 Publication

## Product Specific Information

MA5-13398 targets Thrombospondin in FACS, ICC/IF, IHC (P), IM, IP, and WB applications and shows reactivity with Bovine, Canine, Equine, Human, mouse, Ovine, Porcine, and Rat samples.

The MA5-13398 immunogen is reduced and alkylated purified human TSP (fully denatured) from the supernatant of thrombin-activated platelets.

## Advanced Verification Data




### Thrombospondin 1 Antibody (MA5-13398)

FIGURE 5. Efb interacts with platelet P-selectin. A , human platelets were ultrasonicated in the presence or absence of 3 mg/ml added fibrinogen. Sigma His-Select HF nickel affinity gel was used to capture His-tagged Efb- or Efb-N-interacting proteins from platelet lysates. Affinity precipitates were separated by SDS-PAGE and immunoblotted for integrin alphaIIb, P-selectin, multimerin-1, fibronectin, thrombospondin-1 (indicated by Thrombosp.-1 ), and His tag (to confirm Efb/Efb-N expression and immobilization). Immunoblots shown here are representative of those from three independent experiments. -ve , negative control; PD , pull-down. B , SPR data confirm the direct interaction of Efb and P-selectin. Recombinant P-selectin-Fc immobilized on COOHV-coated SensiQ™ sensor chips was treated with increasing concentrations of Efb (100 nM ( brown ), 300 nM ( purple ), and 2.8 μM ( green )). All experiments were performed using the SensiQ™ Pioneer FE SPR platform (SensiQ Technologies). Experimental data were fit using the Qdat data analysis software. Curves were fitted using a least squares fitting algorithm. RU , response units. Cell treatment validation info.


### Thrombospondin 1 Antibody (MA5-13398)

Figure 4 Astrocytic Ca<sup>2+</sup>-dependent upregulation of TSP-1 in S1 cortex following PSL injury. ( A ) TSP-1 protein levels in S1 cortex measured with ELISA in P8 positive control, sham control, PSL-early, and PSL-late mice. n = 3-4 mice/group. \* P < 0.05 versus sham control or PSL-late mice, by 1-way ANOVA. Inset graph: S1 cortex TSP-1 levels in sham and PSL-early IP 3 R2-KO mice ( n = 3/group). No significant difference was observed between groups ( P > 0.05, by unpaired t test). ( B ) Extracellular TSP-1 levels in S1 cortex following PSL injury measured with ELISA using in vivo microdialysate samples. Extracellular TSP-1 levels significantly increased following PSL injury, peaked at 3 to 6 days after injury, and subsequently decreased to baseline levels ( n = 6 mice/group). \* P < 0.05 and \*\* P < 0.01 versus pre-injury levels, by 1-way ANOVA. ( C ) Top: Representative FISH images of Tsp1 mRNA (red) and immunohistochemical staining of astrocytes (GFAP, green) with DAPI staining (blue). Scale bars: 10 μm and 5 μm (magnified images). Solid arrowheads indicate representative GFAP + and Tsp1 mRNA + cells. Open arrowheads indicate representative GFAP + and Tsp1 mRNA - cells. Arrows indicate representative GFAP - and Tsp1 mRNA + cells. Bottom: Proportion of Tsp1 mRNA + cells in GFAP + and GFAP - cells normalized to the proportion in the sham group. n = 15 image sections/5 mice for sham and 12 sections/4 mice for the PSL-injured group (3 sections/mouse). \*\*\* P < 0.001 and NS ( P > 0 Knockdown validation info.



### Thrombospondin 1 Antibody (MA5-13398)

Figure 5 TSP-1 released from S1 astrocytes following PSL injury promotes synaptic rewiring and sustained mechanical allodynia. (A) Images of the same S1 apical dendrite before and 3 days after PSL injury with sustained (Elvax) saline or gabapentin application. Arrowheads indicate spine formation (red) and elimination (blue). Scale bar: 2  $\mu$ m. Graphs: Spine formation (top) and elimination (bottom) rates in saline-administered, sham-operated mice (n = 24 dendrites/3 mice), PSL-injured mice (n = 17 dendrites/3 mice), and gabapentin-infused, PSL-injured mice (n = 21 dendrites/3 mice). \*\*P < 0.01 and \*\*\*P < 0.001, by 1-way ANOVA. (B) Mean mechanical thresholds following PSL injury in control (n = 7), gabapentin-infused (n = 5), and TSP-1 siRNA-injected (n = 6) mice. \*P < 0.05, \*\*P < 0.01, and \*\*\*P < 0.001 versus control, by 1-way ANOVA. (C) Western blots demonstrate selective knockdown of TSP-1 expression in S1 cortex following TSP-1 siRNA injection. As for positive control of TSP-1, recombinant human TSP-1 (hTSP-1) was loaded (left band). Graphs: Quantitative analysis of Western blots (n = 4). \*\*P < 0.01, by unpaired t test. Spine formation (left) and elimination (right) rates in control siRNA-injected mice (siControl, n = 11 dendrites/3 mice) and TSP-1 siRNA-injected mice (siTSP-1, n = 8 dendrites/2 mice). \*\*P < 0.01, by unpaired t test. (D) Single injection of TSP-1 protein (n = 6 mice), but not PBS (n = 6), into S1 cortex induced mechanical hypersensitivity that lasted at least 21 days.



[View more figures on thermofisher.com](https://www.thermofisher.com)

## Western Blot (52)

### Cells

#### High Glucose Treatment Limits Drosha Protein Expression and Alters AngiomiR Maturation in Microvascular Primary Endothelial Cells via an Mdm2-dependent Mechanism.

"Published figure using Thrombospondin 1 monoclonal antibody (Product # MA5-13398) in Western Blot"

Authors: Lam B,Nwadozi E,Haas TL,Birot O,Roudier E

**Species**  
Not Applicable

**Dilution**  
Not Cited

**Year**  
2021

### Cellular and molecular life sciences : CMLS

#### hnRNPA2B1 inhibits the exosomal export of miR-503 in endothelial cells.

"MA5-13398 was used in Western Blotting to understand the mechanisms of chemotherapeutic drug epirubicin increasing the exosomal export of miR-503 in endothelial cells."

Authors: Pérez-Boza J,Boeckx A,Lion M,Dequiedt F,Struman I

**Species**  
Human

**Dilution**  
Not Cited

**Year**  
2020

[View more WB references on thermofisher.com](#)

## Immunohistochemistry (42)

### PloS one

#### Long-term gene therapy with thrombospondin 2 inhibits TGF- activation, inflammation and angiogenesis in chronic allograft nephropathy.

"MA5-13398 was used in immunohistochemistry to study TGF-beta activation, inflammation and angiogenesis following long-term thrombospondin-2 gene therapy in a model of chronic allograft nephropathy"

Authors: Daniel C,Vogelbacher R,Stief A,Grigo C,Hugo C

**Species**  
Rat

**Dilution**  
Not Cited

**Year**  
2015

### Journal of the American Heart Association

#### Novel tissue-specific mechanism of regulation of angiogenesis and cancer growth in response to hyperglycemia.

"MA5-13398 was used in immunohistochemistry to study the role of miRNA-467 in the tissue-specific hyperglycemic regulation of angiogenesis and cancer cell growth"

Authors: Bhattacharyya S,Sul K,Krukovets I,Nestor C,Li J,Adognravi OS

**Species**  
Human

**Dilution**  
1:50

**Year**  
2012

[View more IHC references on thermofisher.com](#)

## More applications with references on thermofisher.com

IHC (P) (2)   IHC (F) (1)   ICC/IF (6)   ELISA (3)   IP (3)   Neu (4)   DB (2)   Misc (1)

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization. Products are warranted to operate or perform substantially in conformance with published Product specifications in effect at the time of sale, as set forth in the Production documentation, specifications and/or accompanying package inserts ("Documentation"). No claim of suitability for use in applications regulated by FDA is made. The warranty provided herein is valid only when used by properly trained individuals. Unless otherwise stated in the Documentation, this warranty is limited to one year from date of shipment when the Product is subjected to normal, proper and intended usage. This warranty does not extend to anyone other than the Buyer. Any model or sample furnished to Buyer is merely illustrative of the general type and quality of goods and does not represent that any Product will conform to such model or sample. NO OTHER WARRANTIES, EXPRESS OR IMPLIED, ARE GRANTED INCLUDING WITHOUT LIMITATION, IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, OR NON INFRINGEMENT. BUYER'S EXCLUSIVE REMEDY FOR NON-CONFORMING PRODUCTS DURING THE WARRANTY PERIOD IS LIMITED TO REPAIR, REPLACEMENT OF OR REFUND FOR THE NON-CONFORMING PRODUCT(S) AT SELLER'S SOLE OPTION. THERE IS NO OBLIGATION TO REPAIR, REPLACE OR REFUND FOR PRODUCTS AS THE RESULT OF (I) ACCIDENT, DISASTER OR EVENT OF FORCE MAJEURE, (II) MISUSE, FAULT OR NEGLIGENCE OF OR BY BUYER, (III) USE OF THE PRODUCTS IN A MANNER FOR WHICH THEY WERE NOT DESIGNED, OR (IV) IMPROPER STORAGE AND HANDLING OF THE PRODUCTS. Unless otherwise expressly stated on the Product or in the documentation accompanying the Product, the Product is intended for research only and is not to be used for any other purpose, including without limitation, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses, or any type of consumption by or application to human or animals.